Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: Design Therapeutics Inc., 3 years.
Design Therapeutics Inc.
Director
CRISPR Therapeutics AG
Director
Nkarta Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Design Therapeutics Inc. June 9, 202679.3%
-
CRISPR Therapeutics AG June 4, 202697.5%
-
CRISPR Therapeutics AG June 5, 202597.8%
-
Nkarta Inc. June 3, 202598.9%
-
CRISPR Therapeutics AG May 30, 202476.9%
-
CRISPR Therapeutics AG June 8, 202395.4%
-
Design Therapeutics Inc. May 31, 202396.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +474,048 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +139,366 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +59,692 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +61,762 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +683,817 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | In-the-money exercise | +191,541 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Open-market sale | −1,065 | $18.00 | $19,170 |
| May 11, 2026 | Odyssey Therapeutics Inc. | Open-market purchase | +222,222 | $18.00 | $3,999,996 |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +118,512 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +255,823 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +204,658 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +20,582 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Derivative conversion | +166,168 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | In-the-money exercise | +49,850 | — | — |
| May 11, 2026 | Odyssey Therapeutics Inc. | Open-market sale | −277 | $18.00 | $4,986 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.